Table 1.

The multiple drug design strategy and potential multiple drug combination for stage 1 and 4 cancers.

	Stage 1 bladder cancer	Stage 4 bladder cancer
The highly expressed genes for potential inhibition strategy of multiple drug design	ADRM1, COPS5, PSMD8, SUMO2, CALR, PDIA3, DNAJB11, HSPA5, RPN1, CUL1, HSP90B1, KPNA2, PSMD12, ECT2, TK1, TUBA1C, HN1, and ENO1	ADRM1, COPS5, PSMD8, SUMO2, RNF126, CALR, PDIA3, DNAJB11, HSPA5, RPN1, HSP90AA1, HSPA1B, METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1
The suppressed genes for potential activation strategy of multiple drug design	UBC, JUN, RARRES3, and FOS	BCL3, FOS, UBC, and GTF2A1
The nondifferentially expressed genes to avoid side-effect of multiple drug design	BAG6, HUWE1, PAAF1, PSMD10, FAF2, PCYT1A, and PSMD10	BAG6, HUWE1, PAAF1, PSMD10, FAF2, PCYT1A, and PSMD10
The potential multiple drug combination